OR07-2
3-year and 5-year Survival Outcomes in Patients Undergoing VIV-TAVI with and without Bioprosthetic Valve Fracture (BVF)
Marvin Amen, Kettering Health Network, Dayton, OH
Damian N. Valencia, MD1, Karley Fischer, MD1, Yulith Roca Alvarez, MD1, Joshua Ahier, MD1, Thomas Merle, MD1, Marvin Amen2, Peter Pavlina, MD1, Raja A. Nazir, MD1 and Brian Schwartz, MD, FSCAI1, (1)Kettering Health, Kettering, OH, (2)Kettering Health Network, Dayton, OH
Keywords: TAVI/TAVR/Aortic Valve
Background:
Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) for the treatment of bioprosthetic aortic valve degeneration is increasing in favorability for patients of moderate to high surgical risk. The safety, efficacy and durability of bioprosthetic valve fracture (BVF) in patients undergoing ViV-TAVI remain understudied. We sought to compare 3-year and 5-year survival of patients who underwent ViV-TAVI with and without BVF.
Methods:
Patients (n=64) who underwent ViV-TAVI at our institution (Kettering Health, Kettering, Ohio) between 2015 and 2020 for severe symptomatic bioprosthetic valve stenosis were divided into two groups, ViV-TAVI with BVF (n=20) and ViV-TAVI without BVF (n=44). BVF was performed at the time of implantation in patients with residual transvalvular gradients greater than 20 mmHg. 3-year and 5-year survival outcomes were obtained. Kaplan-Meier survival analysis was performed using SPSS software.
Results:
The average age of patients who underwent ViV-TAVI with BVF was 74.5 years and ViV-TAVI without BVF was 77.7 years. At 3 years, there was a 90.5% survival rate in patients who underwent ViV-TAVI with BVF, compared to 79.1% in patients who underwent ViV-TAVI without BVF. At 5 years, there was an 84.6% survival rate in patients who underwent ViV-TAVI with BVF, compared to 75% in patients who underwent ViV-TAVI without BVF.
Conclusions:
At 3-year and 5-year followup, ViV-TAVI with BVF was associated with reduced all cause mortality compared to ViV-TAVI without BVF.